Cat. No. 4541
Chemical Name: 1-[3-[[[(2R,3S,4R,5R)-5-(4-Amino-5-
Biological ActivityHighly potent DOT1L methyltransferase inhibitor (Kd = 0.06 nM, IC50 = 0.3 nM in a radioactive assay); blocks H3K79 methylation in A431 cells and MCF10A cells. Inactive at 12 histone methyltransferases and DNMT1. Selectively kills cells transformed with the MLL-AF9 fusion oncogene in an in vitro model of leukemia; lowers levels of MLL target genes HOXA9 and Meis1.
Licensing InformationThis probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the SGC 0946 probe summary on the SGC website.
External Portal InformationChemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of SGC 0946 is reviewed on the chemical probes website.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Yu et al (2012) Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat.Commun. 3 1288. PMID: 23250418.
If you know of a relevant reference for SGC 0946 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses SGC 0946 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: SGC 0946, supplier, SGC0946, epigenetics, DOT1L, histone, protein, methyltransferase, PKMTs, H3K79me, potent, selective, inhibitors, inhibits, leukemia, MLL, target, genes, Tocris Bioscience, Lysine Methyltransferase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Highly potent and SAM-competitive EZH2 inhibitorGSK 591 dihydrochloride
Potent and selective PRMT5 inhibitorTP 064
Potent and selective PRMT 4 inhibitor
Tocris has a collaboration with the Structural Genomics Consortium (SGC) to provide the latest high quality epigenetics probes.